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. INTRODUCTION
Studies to develop a potent and effective antimicrobial compound are important not only for the control of serious infections, but also for the prevention and treatment of possible infections due to other treatments such as cancer, surgical procedures. Fungal infections increase in the suppression of immune system such as tuberculosis, cancer, AIDS and organ transplantation and it can be the cause of death [1] [2] [3] . For these reasons, the development of antifungal compounds with a broad spectrum of activity, minimized side effects is an important issue.
Hospital infections continue to be the focus of attention due to social problems brought along with mortality, morbidity and cost increases. Hospital infections occur in 5 to 10% of hospital admissions, most commonly in the form of urinary tract infection, surgical site infection, respiratory infection and bacteremia. Bacteremia is an important group in nosocomial infections [4, 5] . Despite the advances in antibiotic therapy and all the improvements in intensive care conditions, mortality is still high and varies between 18-50%. In recent years, although the incidence of gram-negative bacteria has been reported to be low among nosocomial bacteremia factors, it still remains important [6] .
Among the pharmacophore groups which is responsible for antimicrobial activity, the 3(2H)pyridazinone skeleton is one of the important structures used in the synthesis of more effective and broad spectrum antimicrobials [7] [8] [9] [10] [11] [12] [13] [14] .
Budhlakoti et al. performed the synthesis of a new series of pyridazin-3-one derivative compounds and evaluated their antibacterial activity by in vitro disk diffusion method. They reported that the compounds which are obtained by them, 4-benzylidene-6-phenyl-4,5-dihydropyridazin-3(2H)-one and 4-benzylidene-6-(4-chlorophenyl)-4,5-dihydropyridazin-3(2H)-one, showed good antimicrobial activity against S. aureus and S. epidermidis. It is also reported that the other compounds, 4-(4-chlorobenzylidene)-6-phenyl-4,5-dihydropyridazin-3(2H)-one and 4-(4-methoxybenzylidene)-6-(4-chlorophenyl)-4,5-dihydropyridazin-3(2H)one showed good antimicrobial activity against P. euroginosa and E. coli [9] (Figure 1 ). Nagle et al. synthesized the new pyridazinone derivative compounds containing the thymol structure and evaluated the antibacterial activity against E. coli and S. aureus and antifungal activity against A. niger and P. marneffei of these compounds and thymol by agar well diffusion method. They reported that all compounds showed bactericidal and fungicidal activity compared with ciprofloxacin and fluconazole. In this study, molecular modelling studies of synthesized compounds against glucosamine-6-phosphate synthase and A. niger phytase enzymes have also been made and it has been reported that compounds show high binding affinity to receptors [11] (Figure 3 ). Based on the above literatures, the synthesis of new 3(2H)-pyridazinone derivative compounds was carried out and the antibacterial-antifungal activities of these compounds were investigated. In the series of compounds prepared using different benzaldehyde derivatives, the contribution of different substituents on the phenyl ring to activity was investigated and it was aimed to find the precursor molecule for activity. For evaluation of antimicrobial activity, the minimum inhibitor concentration (MIC) values of the compounds were determined against standard ampicillin, gentamicin, ofloxacin, rifampicin, ampicillin-sulbactam, amoxicillin-clavulonic acid, fluconazole and amphotericin B. Binding interactions of these compounds in C. albicans CYP51 (CACYP51) were predicted through molecular docking using a number of free software.
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RESULTS AND DISCUSSION
Chemistry
6-(Substitutedphenyl)-3(2H)-pyridazinone-2-acetyl-2-(substitutedbenzal)hydrazine (D1a-D1d, D2a-D2d) derivatives were synthesized according to Figure 4 . Synthesis of the compounds were initiated by obtaining compound A1, A2 with a very useful and easy-to-use method which Schmidt and Druey developed in 1954 for synthesis of pyridazinone compounds [15] . The reaction is based on the formation of 3(2H)-pyridazinone derivatives by condensation of 1,2-dicarbonyl compound with monosubstituted or unsubstituted hydrazine and the carboxyl derivative containing active methylene group. Dicarbonyl compounds including 1,2diketones, α-ketoacids or glyoxal and esters, malonic acid, acetoacetic acid, cyanoacetic acid, benzoylacetic acid or hippuric acid esters are used as α-methylene reactive group [16] . In this study, glyoxalic acide was used as 1,2-dicarbonyl compound. Glyoxalic acid and acetophenone derivatives were heated with hydrazine hydrate in acidic medium to give 3(2H)-pyridazinone derivatives (A1, A2). Ethyl 6-substituted-3(2H)pyridazinone-2-ylacetate derivatives (B1, B) were obtained by the reaction of A1, A2 with ethyl bromoacetate in the presence of K2CO3 in acetone [17] . Then, 6-substituted-3(2H)-pyridazinone-2-ylacetohydrazide derivatives (C1, C2) were synthesized by the condensation reaction of B1, B2 with hydrazine hydrate [17] . Ultimately, the title compounds bearing benzalhydrazone structure were obtained by the reaction of C1, C2
with substituted/nonsubstituted benzaldehydes. All of the title compounds were reported for the first time in this study. The physical and spectral properties of the starting compounds were in accordance with the literature [18] . Their chemical structures were confirmed by IR, 1 H-NMR and mass spectral data. Synthesized pathway of D1a-D1d, D2a-D2d have been given in Figure 4 . The melting point, yield, molecular formula and spectral data of all compounds are reported in Table 1 and Table 2 . Table 3 ). In general, the compounds showed more potent against fungus than bacterias. Generally, compounds with chloride were more active than those with bromide as R1 substituent. However, D2a stood out as the most active compound in the series with lower MIC values than those of fluconazole against Candida krusei. The derivatives carrying the aromatic ring as the substituent in the hydrazide group in chlorinated compounds exhibited higher activity while the compound containing the trifluoromethyl substituent (D1a) showed low activity. In contrast, aromatic substituents in brominated compounds caused a reduction in activity, while trifluoromethyl containing compound D2a was found to be the most active compound. The results of molecular modelling confirmed this situation.
Antimicrobial activity
Molecular modelling
Molecular modelling studies have been carried out to predict the mechanism of action of antifungal activity because of the moderate antifungal activity of the compounds. Molecular modelling studies have screened whether compounds inhibit the CYP51 enzyme of Candida albicans [19] . The model includes VT1161, a tight binder of CYP51 in the catalytic site. Because of its structural similarity to the compounds that we synthesized, the enzyme to which this ligand is bound was selected (5TZ1).
A redocking study was performed in order to evaluate how close the software/algorithms used in this study predicted the binding mode of VT116 regarding its original conformation in CACYP51 catalytic site. The results confirmed that the methods worked well (Table 4 ). Docking studies showed that D2a bound to the catalytic site of CACYP51 with high affinity (Table 5 ) and in a similar way determined for azole antifungals in crystallography studies ( Figure 5 ). According to the binding modes obtained from several software and algorithms the 4-trifluoromethylbenzen ring placed close to the heme and Fe +2 , the 4-bromobenzen fit in the cleft surrounded by His377 making pi-pi stacking and the tail groups interacted with residues that form the active site gorge, e.g. Gly303, Ile131, Thr122, Thr122, Leu121, Tyr118, Leu376, Phe233 ( Figure 5, Figure 6 ) [20] . Molecular modelling studies were also conducted for the fluconazole compound, which is used as a reference compound in in vitro studies. Although the binding profiles of the fluconazole compound are lower than the D2a compound, the fluconazole compound shows higher efficacy against Candida albicans. This suggests that fluconazole has activity over a different pathway or that the compound we synthesized may not have reached the enzyme site at sufficient concentration in in vitro cell studies. Table 3 . In vitro antibacterial and antifungal activity of 6-Substituted-3(2H)-pyridazinone-2-acetyl-2-(substituted benzal)hydrazone derivatives (D1a-D1d, D2a-D2d Hem601 Phe233 Hem601
CONCLUSION
As sustenance of our research interest in developing novel pyridazinone derivative antimicrobial compounds and establishing new relationships between their structure and activity, we designed and synthesized eight new 6-substituted-3(2H)-pyridazinone derivatives and evaluated their antimicrobial activities. All compounds showed antibacterial activity at 16-64µg/ml concentration and antifungal activity at 8-32µg/ml concentration. We reached one hit molecules, namely D2a, the latter of which showed good activity against standard S. aureus isolat, C. albicans and C. krusei.
We docked D2a to the catalytic site of the CACYP51 homology model featuring full membrane spanning anchor domain, which we previously reported, using two different software/algorithms. These findings together show that D2a may be evaluated as developed precursor compound, could act through CYP51 inhibition.
MATERIALS AND METHODS
Materials
All chemicals used in this study were purchased from Aldrich, Fluka AG and E. Merck. 6-substitute-3(2H)-pyridazinones, ethyl 6-substitute-3(2H)-pyridazinon-2-yl acetates and 6-substitute-3(2H)-pyridazinon-2-yl acetohydrazides were synthesized according to literature methods [11] [12] [13] . Analytical thin-layer chromatography (TLC) was performed on plates precoated with silica gel (Merck Kieselgel F254 plates. Melting points of the compounds were determined on Electrothermal 9200 melting points apparatus (Southent, Great Britain) and the values given are uncorrected. The IR spectra of the compounds were recorded on a Bruker Vector 22 IR spectrophotometer (Bruker Analytische Messtechnik, Karlsrure, Germany). The 1 H-NMR and 13 C-NMR of the compounds spectra were recorded on a Bruker Avonce 300 MHz Ultrashield TM NMR Spectrometer using tetramethylsilane as an internal standard at İnönü University and Ankara University. All the chemical shifts were recorded as  (ppm). High resolution mass spectra data (HRMS) were collected in house using a Waters LCT Premier XE Mass Spectrometer (high sensitivity orthogonal acceleration time-offlight instrument) operating in ESI () method, also coupled to an AQUITY Ultra Performance Liquid Chromatography system (Waters Corporation, Milford, MA, USA). IR spectra were obtained using a Perkin Elmer Spectrum 400 FTIR/FTNIR spectrometer equipped with a Universal ATR Sampling Accessory. 
Methods
Chemistry
The fine chemicals and all solvents used in this study were purchased locally from E. Merck (Darmstadt, F. R. Germany) and Aldrich Chemical Co. (Steinheim, Germany).
Synthesis of 6-(4-chloro/4-bromophenyl)-3(2H)-pyridazinone A1, A2
Glyoxylic acid (0.05 mol) and (0.15 mol) 4-chloro/bromoacetophenone were heated at 100-105 o C for 2 h. At the end of this period, the reaction mixture was cooled to 40 º C and then, 20 mL water and 5 mL ammonium hydroxide solution (25 %) were added to the reaction mixture until the medium pH became 8. Then, reaction mixture was extracted with dichloromethane. Hydrazine hydrate (0.05 mol) was added to the separated aqueous layer and the reaction mixture was refluxed for 2 h. After the completion of the reaction, reaction mixture was cooled to room temperature. The resulting precipitate was filtered to give compounds A1, A2. The measured melting points for A1 and A2 were in agreement with the literature (A1 found: 239-241 º C, A1 literature: 235-237 º C; A2: 263-265 º C) [14, 21] .
Synthesis of ethyl 6-(4-chloro/4-bromophenyl)-3(2H)-pyridazinone-2-ylacetate B1, B2
A mixture of 0.01 mol 6-(4-chloro/4-bromophenyl)-3(2H)-pyridazinone derivatives A1, A2, 0.02 mol (2.2252 ml) ethyl bromoacetate, and 0.02 mol (2.7636 g) potassium carbonate in acetone (40 ml) was refluxed overnight. After the mixture was cooled, the organic precipitat were filtered off, the solvent was evaporated, and the residue was purified by recrystallization with methanol to give the esters. The measured melting points for B1 and B2 were in agreement with the literature (B1 found: 172-174 º C, B1 literature: 171-172 º C; B2 found: 167-169 º C; B2 literature: 164-166 º C) [12, 22, 23] .
Synthesis of 6-(4-chloro/4-bromophenyl)-3(2H)-pyridazinone-2-yl acetohydrazide C1, C2
Hydrazine hydrate (99%, 3ml) was added to the solution of 0.01 mol ethyl 6-(4-chloro/4-bromophenyl)-3(2H)-pyridazinone-2-yl acetate derivatives B1, B2 in 25 ml methanol and stirred for 3h at room temperature. The precipitate obtained was filtered off, washed with water, dried, and recrystallized from ethanol. The measured melting points for C1 and C2 were in agreement with the literature (C1 found: 226-228 o C, C1 literature: 223-226 º C; C2 found: 202-204 º C; C2 literature: 204-205 º C) [13, 24, 25] .
General procedure for synthesis of 6-(4-chloro/4-bromophenyl)-3(2H)-pyridazinone-2-acetyl-2-(substituted/ nonsubstituted benzal)hydrazonederivatives D1a-D1d, D2a-D2d
Mixture of 6-(4-chloro/4-bromophenyl)-3(2H)-pyridazinone-2-yl-acetohydrazide derivatives C1, C2 (0.01 mol) and appropriate non substituted/substituted benzaldehyde (0.01 mol) were refluxed in 15 mL ethanol for 6 h. Then the mixture was poured into ice-water. The precipitate formed was recrystallized from appropriate solvent.
Antibacterial and antifungal activity
Material
The following bacteria were used for antibacterial study: Standard strains of Escherichia coli ATCC 25922, Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212. The following yeast-like fungi were used for antifungal study; Candida albicans ATCC 10231 and Candida krusei ATCC 6258.
Inoculation suspensions
The microorganism suspensions used for inoculation were prepared at 10 6 cfu/ml concentration by diluting of the fresh cultures at McFarland 0.5 density (10 8 cfu/ml). It was known that there were 5x10 4 cfu/ml microorganisms in each well after inoculation.
Medium
Mueller Hinton Broth (Oxoid) liquid nutrient medium was used for diluting of microorganism suspension and two fold-dilution of the compounds. Sabouraud liquid medium (Oxoid) was used for yeast like fungi for the same purpose.
Equipment
Falcon R microplates which have 96 wells were used for microdilution method. Brinkmann transferpette was used for two fold-dilution of compounds in the wells.
Microdilution Method
Microdilution method was employed for antibacterial and antifungal activity tests [26] . The synthesized compound and the standarts ampicillin trihydrate and fluconazole were dissolved in DMSO at 1000 g/ml concentration at the beginning. The solution of each compounds at 500-3.9 g/ml were prepared in the wells by diluting with the mediums. Suspension of the microorganisms at 10 6 cfu/ml concentration were inoculated to the twofold-diluted solution of the compounds, consequently the microorganism concentration in each well was approximately 5x10 4 cfu/ml. DMSO-microorganisms mixture, the pure microorganisms, and pure media were used as control wells.
Microplates were covered and incubated at 36ºC for 24-48 hours. Wet cotton-wool was placed in the incubation chamber, because it should be kept sufficiently to avoid evaporation. After this period of time, evaluation of the wells was performed. The concentration of the compounds in the wells where no growth was assessed as the minimum inhibitory concentration (MIC) of the compounds. There was no inhibitory activity in the wells containing only DMSO. The microbial growth occurred, and the medium were not contaminated during the tests. The MIC values of 6-substituted-3(2H)-pyridazinone-2-yl acetyl-2-(psubstitutedbenzal)hydrazone D1a-D1d, D2a-D2d derivatives were given in Table 3 .
Molecular modelling studies
Molecular docking studies are currently gaining much attention in the field of medicinal chemistry. The significant experimental antifungal activities of D2a provide a hint to performing molecular docking studies to understand the protein-ligand interactions. We prepared and optimized the ligands using ChemDraw and Chem3D (2015). Molecular docking studies were performed using AutoDock (v4.2.6) [19] , AutoDock Vina (v1.1.2) [27] and AutoDockTools (v1.5.6) [19] . We downloaded the crystal structure of Candida albicans lanosterol 14α-demethylase (PDB ID: 5TZ1 [28] ) from RCSB Protein DataBank (http://www.rcsb.org/) [29] . We removed the water molecules and unwanted residues from the protein, added hydrogens and Gasteiger charges to it. We created grid maps of the receptor using the central coordinates of the co-crystallized ligand, VT1161, setting the grid spacing as 0.375 Å and the grid box dimensions as large as to accommodate the ligands. Each ligand was docked to the receptor 50 times at full flexibility and medium exhaustiveness using Lamarckian genetic algorithm. The output conformations were clustered and analysed according to their RMSD values and docking scores. The best conformations were picked according to visual evaluation.
